NanoSmart™ Pharmaceuticals, Inc., a California corporation developing novel biopharmaceuticals, is pleased to report that it has received a Notice of Allowance for a US patent on its proprietary cancer tumor targeting technology.
"We have taken an approach to targeting tumors that is different from other companies," said Dr. Henry Smith, CEO of the company. "While most of cancer research has focused on developing antibodies to specific tumor antigens, we realized that it was possible to target normal cellular material that is inappropriately expressed within the tumor mass. Many tumors contain areas of necrosis where dead cells have ruptured and emptied their intracellular material into the extracellular environment. We have developed a fully-human antibody to target this material, and use it as an agent to transport cancer drugs to the tumor site where they would have the most effect."
Study shows AI can predict prognosis in triple-negative breast cancer